Increased mTOR activation in idiopathic multicentric Castleman disease.
Level 4 - case-series / case-control
Translational case-control study using human tissue and serum samples
PubMed 32206779 · doi:10.1182/blood.2019002792
What was done
The authors investigated mTORC1 pathway activation in idiopathic multicentric Castleman disease (iMCD). They evaluated lymph node tissue from iMCD patients (N = 26) compared with healthy controls, Hodgkin lymphoma, systemic lupus erythematosus, reactive lymph nodes, and autoimmune lymphoproliferative syndrome using immunohistochemistry (IHC) for mTORC1 effectors (pS6, p4EBP1, p70S6K). They performed gene set enrichment analysis on serum proteomic profiles from iMCD patients (n = 88) and controls (n = 42), and conducted functional assays measuring baseline mTOR activation, response to IL-6 stimulation, and response to JAK1/2 inhibition in peripheral monocytes and T cells during remission.
What was found
IHC demonstrated increased mTORC1 activation in the interfollicular space of iMCD lymph nodes compared to controls, Hodgkin lymphoma, lupus, and reactive lymph nodes, reaching levels comparable to autoimmune lymphoproliferative syndrome. Serum proteomics showed significant enrichment of mTORC1 signaling pathways in iMCD patients compared to controls. Peripheral blood monocytes and T cells in remission had elevated baseline mTOR activation that increased further with IL-6 stimulation and was abrogated by JAK1/2 inhibition. Exact numerical values, test statistics, and p-values were not reported in the abstract.
Why it matters
This study establishes mTORC1 hyperactivation across tissue, serum, and circulating immune cells in iMCD. It provides mechanistic rationale for clinical evaluation of mTOR inhibitors such as sirolimus, particularly in patients who do not respond to anti-IL-6 therapy.
Limits
The abstract reports no numerical effect sizes, test statistics, confidence intervals, or p-values. The study is observational and translational using retrospective tissue and serum samples rather than a clinical trial assessing patient outcomes. Sample sizes and clinical details for the functional cellular assays are not specified in the abstract.
Cited by
- supports Dr. David Fajgenbaum was diagnosed with Castleman disease, treated himself with a combination of approved drugs, and has survived over 11 years following his terminal prognosis.
- supports A 13-year-old pediatric patient with life-threatening Castleman disease at Children's Hospital of Philadelphia achieved disease reversal and remission following treatment with sirolimus.